Eli Lilly and Co stock

What is Eli Lilly and Co?

Eli Lilly & Co. is a renowned pharmaceutical company headquartered in Indianapolis, Indiana with a global presence in over 120 countries. With a workforce of 35,000 full-time employees, the firm specializes in the discovery, development, manufacturing, and sale of various human pharmaceutical products. The company offers a diverse range of products, including diabetes products such as Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity, oncology products like Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio, and immunology products such as Olumiant, Baricitinib, and Taltz. Additionally, it provides neuroscience products like Cymbalta, Emgality, and Zyprexa, and other therapies such as Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. As a major player in the pharmaceutical industry, the company caters to various market segments, including wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. Investors who want to stay on top of the latest developments can track Eli Lilly & Co.'s share price and market cap. The stock price today, including stocks share price today, is available through various financial news outlets, while premarket trading is also an option for some investors. In conclusion, Eli Lilly & Co. is a leading pharmaceutical company with a strong presence in the global market. Its diverse range of products and customer-focused approach have helped establish its position as a top player in the industry. Investors interested in the company can track its share price, market cap, and other important metrics to make informed investment decisions.

Eli Lilly and Co performance

  • Employees

  • Company HQ

  • Website

  • LLY Asset Type

    Common Stock
  • LLY Market Capitalization

  • Earnings Per Share 6.31
  • Dividends Per Share 4.07
  • Dividend Date 2023-06-09
  • Quarterly Earnings Growth -0.29

Eli Lilly and Company Analytics and Performance


Discover Eli Lilly and Company (LLY), a prominent player in the LIFE SCIENCES sector, specifically within the PHARMACEUTICAL PREPARATIONS industry. As a Common Stock, LLY has a strong presence not only in the United States but also in various countries around the world, including its home base USA.

LLY Financial Performance: Key Ratios and Market Indicators

As of the latest quarter ending 2023-03-31, LLY boasts an EBITDA of 9154000000 and a trailing price-to-earnings ratio (PE ratio) of 70.41. The forward PE ratio stands at 39.06, which indicates stocks potential in earnings. LLY's price-to-sales ratio (TTM) is 11.7, and the price-to-book ratio is 34.06. The company's enterprise value-to-revenue and enterprise value-to-EBITDA ratios are 12.18 and 42.04, respectively.

LLY Stock Stability: Analyzing Marketing Volatility and Trends

LLY stock performance showcases a beta of 0.367, highlighting moderate volatility. The 52-week high and low prices are 454.95 and 279.8, respectively, with a 50-day moving average of 395.5 and a 200-day moving average of 353.38. With 949273000 shares outstanding, LLY demonstrates strong performance in the market.

LLY Dividends: Current Yields and Shareholder Value

In terms of dividends, Eli Lilly and Company has a dividend per share of 4.07 and a dividend yield of 0.0102. The company's most recent dividend date was 2023-06-09, and the ex-dividend date was 2023-05-12. LLY's financials reveal a book value of 12.44 and earnings per share (EPS) of 6.31, with a diluted EPS (TTM) of 6.31.

LLY Revenue and Profitability: Unveiling the Company's Financial Strength

LLY revenue per share (TTM) is 30.73, and its total revenue (TTM) amounts to 27691399000. The company's gross profit (TTM) is 21911600000. LLY's profit margin stands at 0.205, while the operating margin (TTM) is 0.278. The return on assets (TTM) and return on equity (TTM) are 0.0962 and 0.548, respectively.

LLY Growth Prospects: Earnings Growth and Analyst Expectations

LLY has experienced quarterly earnings growth (YOY) of -0.29, but its quarterly revenue growth (YOY) remains stagnant at -0.109. Analysts have set a target price of 436.3 for Eli Lilly and Company stock.

Interested in Eli Lilly and Company? You may be interested in: